News Related to Povetacicept

Related coverage linked through entity extraction aliases.

Vertex completes rolling BLA submission for povetacicept after positive Phase 3 IgAN data

May 05, 2026

Vertex completed the rolling BLA submission for povetacicept in IgA nephropathy after positive Phase 3 RAINIER interim data. The company plans to use a Priority Review Voucher to accelerate FDA review.

Vertex Reports Q4 2025 Revenue of $3.19B, Issues 2026 Guidance of $12.95-13.1B

Feb 13, 2026

Vertex Pharmaceuticals reported fourth quarter 2025 revenue of $3.19 billion, up 10% year-over-year, and provided full year 2026 revenue guidance of $12.95 billion to $13.1 billion with over $500 million expected from non-CF products.